( yIndex (EASI) a commonly applied test...)Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis,Health

y Index (EASI), a commonly applied test for AD. The study participants were randomized into two treatment groups with 18 patients each and received 6 weekly subcutaneous injections of either 300 ?g CYT003-QbG10 or placebo. Two weeks after the last dose, the disease status of the patients was again assessed by the EASI.

About allergic diseases and atopic dermatitis
Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. On the immunological level, so called T helper 2-type (Th2) immune responses are considered crucial for the initiation and maintenance of allergy. The prevalence of allergic diseases has dramatically increased over the last decades, especially in industrialized countries. It is estimated that today more than 20% of the world population suffers from allergic diseases1.

AD is a certain type of eczema. It is a common chronic skin disease considered to be linked to an “allergic” Th2 type immune status of the patients. It most often begins in infancy and an estimated 20% of infants and young children experience disease symptoms. Roughly 60% of those continue to have AD also in adulthood2. Children with AD are at greater risk for developing other allergic diseases like rhinitis or asthma later in life. AD is characterized by a hypersensitivity reaction occurring in the skin that causes chronic inflammation and renders the skin dry, itchy and scaly. Irritants (e.g. wool, soap), allergens and emotional stress exacerbate disease symptoms and further trigger the overactive immune system. There is no cure available. Current medications such as immunomodulators, corticosteroids or antihistamines address disease symptoms only and may be associated with sideeffects, especially upon long-term use.

About CYT003-QbG10
CYT003-QbG10 is an immunotherapeutic product in development for
'"/>




Page: 1 2 3 4 5
Related medicine technology :

1. Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis